Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 108 people who had been diagnosed with endometrial (uterine) cancer and were receiving a type of internal radiation treatment called vaginal cuff brachytherapy. Participants were split into two equal groups of 54: one group received a shorter course of this radiation treatment, and the other received the standard-length course. The trial was measuring quality of life, feelings about femininity, and the cost of treatment. All 108 participants who started the trial completed it. Please note that some planned measurements — including a financial wellbeing questionnaire and questions about diet and physical activity — were not reported in the submitted data. The reported data shows that, one month after treatment, both groups had a very similar small change in their overall quality of life scores (using a 0–100 scale where higher means better quality of life): both the shorter-course group and the standard-course group showed an average increase of 2.08 points from their starting scores. For a question asking whether participants felt less feminine as a result of their disease or treatment (again on a 0–100 scale, where higher means feeling less feminine), the shorter-course group showed a small average increase of 0.65 points, while the standard-course group showed an average decrease of 6.25 points. The reported data does not include further detail explaining this difference. Regarding costs, the reported data shows that the average amount charged for procedures was approximately USD $33,205 for the shorter-course group and approximately USD $45,920 for the standard-course group — a difference of roughly USD $12,700. These figures reflect charges in the United States and may not be directly relevant to the Australian healthcare setting. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 19367689) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a confirmed type of uterine (endometrial) cancer — including endometrioid, serous, clear cell, carcinosarcoma, or other sarcomas — where the cancer started mainly in the uterus, and where a specific internal radiation treatment called vaginal cuff brachytherapy has been recommended.
- People whose cancer is at a specific stage and grade combination: Stage IA (grade 1 with a specific spread pattern, or grades 2–3), Stage IB (grades 1–3), Stage II (grades 1–3), or Stage IIIA (grades 1–3, but only if not receiving external beam radiation therapy as part of their treatment).
- People who have already had a hysterectomy (surgical removal of the uterus) and have no remaining signs of cancer.
- People with a general health and activity level rated between 0 and 2 on a standard medical scale — meaning they are fully active to capable of basic self-care (confirm with trial site).
- People who are willing and able to give informed consent by signing an approved consent form.
- People with a life expectancy of more than 2 years.
Who may not be able to join:
- People whose cancer stage does not match one of the specific stage and grade combinations listed above.
- People who have previously had radiation therapy to the pelvic area.
- People who currently have another cancer that requires anti-cancer treatment (other than surgery) outside of this trial's plan.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cristina DeCesaris, MD, Huntsman Cancer Institute/ University of Utah
Phone: 801-585-0115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Quality of Life From Baseline to 1 Month; Cohort 2: Participant-Reported Financial Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.